Download by
Scanning QR Code
No Stock Yet
Jiuzhou Pharmaceutical (603456): Transforming Small Molecule CDMO's Established Specialty Pharmaceutical Company to Develop Again
Jiuzhou Pharmaceutical (603456): A New Stage of High Quality and Efficient Growth
Jiuzhou Pharmaceutical (603456): CDMO business continues to grow strongly and production capacity continues to expand
Jiuzhou Pharmaceutical (603456): The overall layout leaps forward
Jiuzhou Pharmaceutical (603456): Continuing high growth and gradually improving the integrated multi-functional production capacity layout
Jiuzhou Pharmaceutical (603456): 2022 performance is in line with expectations, CDMO maintains rapid growth
Jiuzhou Pharmaceutical (603456): Performance is in line with expectations, CDMO orders are abundant, production capacity is released smoothly
Jiuzhou Pharmaceutical (603456) Annual Report Review Report: Performance is in line with the previously announced range, and the number of rapid growth projects in the CDMO sector increased rapidly
Jiuzhou Pharmaceutical (603456) Company Research Report: Binding Novartis to Successfully Transforming CDMO to Accelerate Production Capacity Building, Optimistic about the Company's Future Rapid Development of “AP+Formulation” Integrated CDMO
Jiuzhou Pharmaceutical (603456): Continuing to expand the in-depth development of large customers and build a core platform
Loading...
No Stock Yet